VivoSeq
Oncology

Small Cell Lung Cancer

507

Pipeline Programs↗

173

Active Trials↗

141

Companies Involved↗

Small Cell Lung Cancer is a highly competitive landscape with 507 programs across 141 companies. The most active players are Chipscreen Biosciences, Ltd., Allist Pharmaceuticals, Inc., Legend Biotech USA Inc. 21 therapies are approved with 87 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

96/100

Pipeline Velocity

71/100

Mech. Concentration

6/100

Completion Rate

72/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Chipscreen Biosciences, Ltd.

1 program

Phase 1A

Allist Pharmaceuticals, Inc.

1 program

Phase 1L

Legend Biotech USA Inc

1 program

Phase 1H

Hangzhou DAC Biotechnology Co., Ltd.

1 program

Phase 1G

Guangzhou Ruixin Biotechnological Co., LTD

1 program

Phase 1Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical19

Topotecan Hydrochloride

Gynecologic Oncology Group

Serplulimab

Shanghai Henlius Biotech

Lithium

Solvay Pharmaceuticals

Erlotinib

Dutch Society of Physicians for Pulmonology and Tuberculosis

Tarceva

OSI Pharmaceuticals

Phase 177

Fenretinide

Eastern Cooperative Oncology Group

Lithium Carbonate

Solvay Pharmaceuticals

Chloroquine

Sanofi

Ezabenlimab

Boehringer Ingelheim

Carfilzomib

Virionyx Corporation Limited

Phase 2303

Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Bendamustine Hydrochloride

SymBio Pharmaceuticals

Sintilimab

Innovent Biologics (Suzhou) Co. Ltd.

Adavosertib

AstraZeneca

Ceralasertib

AstraZeneca

Phase 387

Atezolizumab

Roche

Pembrolizumab

Merck & Co.

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Ivonescimab

Summit Therapeutics

Toripalimab

Coherus Oncology, Inc.

Approved21

Ponatinib

Takeda

Carboplatin

Avyxa

Trilaciclib

Pharmacosmos A/S

Gefitinib

AstraZeneca

Pasireotide

RECORDATI GROUP

Analysis

Modality Breakdown

86%

Small molecule

483 of 563 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody509%Protein / enzyme122%Vaccine71%Antibody–drug conjugate3<1%Peptide3<1%Cell therapy3<1%Other2<1%

Small molecule leads; the ring shows all 563 classified programs, each share of the total. Modality classified for 99% of 599 pipeline programs.

Analysis

Trial Status

764

clinical trials

Completed347 · 45%
Unknown status108 · 14%
Terminated107 · 14%
Recruiting79 · 10%
Not yet recruiting49 · 6%
Active, not recruiting42 · 5%
Other32 · 4%

Clinical Trials

Trial Activity

764 trials

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT06437509·66 enrolled
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 3·NCT07189455·420 enrolled
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06562920·20 enrolled
Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
Recruiting·—·Phase 2·NCT07425795·36 enrolled
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Recruiting·SSichuan University·Phase 2·NCT06610734·202 enrolled
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06758700·15 enrolled
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Recruiting·NNerviano Medical Sciences·Phase 1·NCT06931626·10 enrolled
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Recruiting·Amgen logoAmgen·Phase 1·NCT06898957·200 enrolled
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT06500026·714 enrolled
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
Recruiting·—·Phase 2·NCT05588388·39 enrolled
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
Recruiting·UUNICANCER·Phase 2·NCT05617963·100 enrolled
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Recruiting·HHansoh BioMedical R&D Company·Phase 3·NCT06498479·460 enrolled
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
Recruiting·—·Phase 2·NCT06830694·50 enrolled
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Recruiting·Qilu Pharmaceutical Co., Ltd. logoQilu Pharmaceutical Co., Ltd.·Phase 3·NCT06954246·450 enrolled
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
Recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 3·NCT06612151·438 enrolled
Page 1 of 51

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)